Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension

Juby AG, Blackburn TE, Mager DR (2022) Alzheimer's & Dementia Translational Research & Clinical Interventions
Title and abstract of Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension

Key Takeaway

15-month RCT showed MCT oil (42g/day) stabilized cognition in Alzheimer's patients over 9 months of continuous use

Summary

This rigorous study examined the effects of MCT oil supplementation in subjects with probable Alzheimer's disease over an extended period. The study used a crossover design followed by an open-label extension, providing both controlled and long-term observational data.

Methods

  • Design: 6-month randomized, double-blind, placebo-controlled, crossover study with 6-month open-label extension
  • Participants: Adults with probable Alzheimer's disease
  • Intervention: 42g/day MCT oil vs placebo
  • Duration: 15 months total (6 months crossover + 6 months extension)
  • Outcomes: Cognitive assessments, ketone levels

Key Results

  • MCT oil significantly elevated serum ketone bodies
  • Cognitive stabilization observed over 9-month exposure period
  • The trial suggests continuous daily nutritional ketones may stabilize cognition
  • Results support MCT as a potential adjunctive therapy for AD

Figures

Limitations

  • Small sample size limits generalizability
  • Single-center study
  • Compliance challenges with 42g daily dose
  • Open-label extension introduces potential bias
  • Results need replication in larger trials

Related Interventions

Related Studies

Source

View on PubMed →

DOI: 10.1002/trc2.12259